Literature DB >> 19294506

The clinical value of serum connective tissue growth factor in the assessment of liver fibrosis.

Dai Zhang1, Nian-Yue Wang, Cheng-Bao Yang, Guo-Xiang Fang, Wei Liu, Jian Wen, Chan Luo.   

Abstract

To explore the relation between connective tissue growth factor (CTGF) in serum and the severity of liver fibrosis, and to determine the clinical value of CTGF in the assessment of liver fibrosis, serum CTGF was tested utilizing enzyme-linked immunosorbent assay (ELISA). The correlation between serum CTGF concentration and fibrosis stage was assessed. The diagnostic performance of CTGF was assessed by comparing the area under the receiver operating characteristic (ROC) curves (AUC) with a panel of fibrosis markers. The correlation coefficient was 0.689 (P < 0.001) between the levels of serum CTGF and fibrosis stages and the AUC of CTGF was 0.841 (95% confidence interval [CI] 0.762-0.920) in distinguishing mild fibrosis from significant fibrosis. The present data revealed that serum CTGF was significantly correlated with the stage of liver fibrosis, suggested that serum CTGF was an indicator for the stage of liver fibrosis, and shown evidence that serum CTGF could be used as a valuable marker for assessing liver fibrosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19294506     DOI: 10.1007/s10620-009-0781-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  31 in total

1.  Liver biopsy:complications and risk factors.

Authors:  Pornpen Thampanitchawong; Teerha Piratvisuth
Journal:  World J Gastroenterol       Date:  1999-08       Impact factor: 5.742

2.  Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis.

Authors:  S Sato; T Nagaoka; M Hasegawa; T Tamatani; T Nakanishi; M Takigawa; K Takehara
Journal:  J Rheumatol       Date:  2000-01       Impact factor: 4.666

3.  Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP.

Authors:  M R Duncan; K S Frazier; S Abramson; S Williams; H Klapper; X Huang; G R Grotendorst
Journal:  FASEB J       Date:  1999-10       Impact factor: 5.191

4.  Sampling variability of percutaneous liver biopsy in primary sclerosing cholangitis.

Authors:  R Olsson; I Hägerstrand; U Broomé; A Danielsson; G Järnerot; L Lööf; H Prytz; B O Rydén; S Wallerstedt
Journal:  J Clin Pathol       Date:  1995-10       Impact factor: 3.411

5.  Connective tissue growth factor in human liver cirrhosis.

Authors:  M Abou-Shady; H Friess; A Zimmermann; F F di Mola; X Z Guo; H U Baer; M W Büchler
Journal:  Liver       Date:  2000-07

6.  Connective tissue growth factor in serum as a new candidate test for assessment of hepatic fibrosis.

Authors:  Axel M Gressner; Eray Yagmur; Birgit Lahme; Olav Gressner; Sven Stanzel
Journal:  Clin Chem       Date:  2006-07-20       Impact factor: 8.327

7.  Transforming growth factor beta induces anchorage-independent growth of NRK fibroblasts via a connective tissue growth factor-dependent signaling pathway.

Authors:  D Kothapalli; K S Frazier; A Welply; P R Segarini; G R Grotendorst
Journal:  Cell Growth Differ       Date:  1997-01

Review 8.  Roles of TGF-beta in hepatic fibrosis.

Authors:  Axel M Gressner; Ralf Weiskirchen; Katja Breitkopf; Steven Dooley
Journal:  Front Biosci       Date:  2002-04-01

9.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

Authors:  Chun-Tao Wai; Joel K Greenson; Robert J Fontana; John D Kalbfleisch; Jorge A Marrero; Hari S Conjeevaram; Anna S-F Lok
Journal:  Hepatology       Date:  2003-08       Impact factor: 17.425

10.  Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.

Authors:  Robert P Myers; Marie Hélène Tainturier; Vlad Ratziu; Annie Piton; Vincent Thibault; Françoise Imbert-Bismut; Djamila Messous; Frederic Charlotte; Vincent Di Martino; Yves Benhamou; Thierry Poynard
Journal:  J Hepatol       Date:  2003-08       Impact factor: 25.083

View more
  7 in total

1.  Non invasive tools for the diagnosis of liver cirrhosis.

Authors:  Maurizio Soresi; Lydia Giannitrapani; Melchiorre Cervello; Anna Licata; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

2.  Clinical significance of connective tissue growth factor in hepatitis B virus-induced hepatic fibrosis.

Authors:  Rong-Li Piao; David R Brigstock; Jie Zhu; Man-Li Zhang; Run-Ping Gao
Journal:  World J Gastroenterol       Date:  2012-05-14       Impact factor: 5.742

3.  Significance of serum connective tissue growth factor in patients with hepatocellular carcinoma and relationship with angiogenesis.

Authors:  Gui-Bo Wang; Xin-Yu Zhou; Tao Yuan; Jun Xie; Li-Ping Guo; Ning Gao; Xiao-Qin Wang
Journal:  World J Surg       Date:  2010-10       Impact factor: 3.352

Review 4.  Cellular protein markers, therapeutics, and drug delivery strategies in the treatment of diabetes-associated liver fibrosis.

Authors:  Chien-Yu Lin; Pratik Adhikary; Kun Cheng
Journal:  Adv Drug Deliv Rev       Date:  2021-04-20       Impact factor: 17.873

5.  Rapid hepatic clearance of full length CCN-2/CTGF: a putative role for LRP1-mediated endocytosis.

Authors:  K G F Gerritsen; N Bovenschen; T Q Nguyen; D Sprengers; M P Koeners; A N van Koppen; J A Joles; R Goldschmeding; R J Kok
Journal:  J Cell Commun Signal       Date:  2016-09-19       Impact factor: 5.782

6.  Kahweol decreases hepatic fibrosis by inhibiting the expression of connective tissue growth factor via the transforming growth factor-beta signaling pathway.

Authors:  Hye-Young Seo; Yun-A Jung; So-Hee Lee; Jae Seok Hwang; Keun-Gyu Park; Mi-Kyung Kim; Byoung Kuk Jang
Journal:  Oncotarget       Date:  2017-08-01

7.  Galectin-1 gene silencing inhibits the activation and proliferation but induces the apoptosis of hepatic stellate cells from mice with liver fibrosis.

Authors:  Zhi-Jun Jiang; Qing-Hua Shen; Hai-Yong Chen; Zhe Yang; Ming-Qi Shuai; Shu-Sen Zheng
Journal:  Int J Mol Med       Date:  2018-10-23       Impact factor: 4.101

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.